In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation

Track this case

Case Number:

2:17-md-02785

Court:

Kansas

Nature of Suit:

Personal Inj. Prod. Liability

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Daniel D. Crabtree

Firms

Companies

Sectors & Industries:

March 14, 2022
Judge OKs $264M Deal Ending Mylan EpiPen Price-Hike Suit

A Kansas federal court has preliminarily approved a $264 million deal that would end claims that Mylan colluded with Pfizer Inc. to obstruct generic versions of the EpiPen, the emergency drug used to treat severe allergic reactions, from entering the market.
February 28, 2022
Mylan Inks $264M Deal Ending EpiPen Class Price-Hike Suit

Health care company Viatris — formerly known as Mylan — said Monday that it has agreed to a $264 million settlement to resolve class action claims that it conspired with Pfizer Inc. to delay the entry of generic competitors to the emergency allergy treatment EpiPen, allowing it to price gouge consumers.
January 06, 2022
Mylan Can't Exclude Ex-CEO From EpiPen Antitrust Trial

A Kansas federal judge Wednesday rejected Mylan's bid to spare a former CEO from the late January trial in a massive antitrust class action accusing the drugmaker of unlawfully blocking generic rivals to the EpiPen.
December 21, 2021
Mylan Says Unharmed EpiPen Loyalists Undercut Class Cert.

The seller of the EpiPen has urged a Kansas federal judge to reconsider keeping a class of buyers intact in a massive antitrust suit accusing the company of unlawfully blocking generic rivals, saying his decision didn't fully account for brand loyalists whose out-of-pocket costs would have been the same regardless of a generic option.
December 15, 2021
Mylan Can't Decertify EpiPen Antitrust Action Ahead Of Trial

A Kansas federal judge on Wednesday largely denied Mylan's bid ahead of trial next month to decertify antitrust class action claims accusing the pharmaceutical company of causing a delay in the release of cheaper EpiPen generics, finding that the buyers have shown that most class members sustained an alleged injury.
November 17, 2021
Consumer Counsel Gets $115M From EpiPen Settlement

A Kansas federal judge granted final approval to the $345 million settlement between Pfizer and the consumer classes that accused it of scheming to inflate the price of its emergency allergy treatment EpiPen on Wednesday, which includes a $115 million check to class counsel from multiple firms.
October 26, 2021
EpiPen Buyers Can't Appeal Order Yet In Antitrust Case

EpiPen buyers can't immediately appeal an order that dismissed racketeering claims from its case accusing Mylan of scheming to inflate the price of the emergency allergy treatment, a Kansas federal judge has ruled.
September 08, 2021
Mylan Pushes Back Against EpiPen Buyers' Appeal Bid

Mylan urged a Kansas federal judge to dismiss a class of EpiPen buyers' bid to appeal a June order finding that the drug giant cannot face racketeering allegations or claims over rebates for its allergy treatment, arguing that they're simply attempting to relitigate issues the trial court already examined.
July 15, 2021
Pfizer And EpiPen Consumers Reach $345M Deal

Pfizer has reached a $345 million settlement with a class of consumers who allege they overpaid for EpiPens because of anti-competitive practices by pharmaceutical companies, potentially clearing the company from having to face a jury trial scheduled for early next year.
June 25, 2021
Mylan Nabs Partial Win On EpiPen Claims, Still Faces Trial

Mylan will not face racketeering claims or claims over its rebates for the EpiPen in a scheduled September trial in Kansas federal court, but a jury will still hear allegations from consumers that the company delayed the launch of a generic version of the emergency allergy treatment.

← Previous
1
2
3
4
5
Next →